Fresenius Kabi

Fresenius Kabi

Germany - Bad Homburg
Biotechnology2 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Infusion Therapy

Fresenius Kabi is a life sciences company focused on Infusion Therapy.

OncologyInfectious DiseasesImmunologyNephrologyNeurology
Employees
5000+
Open Jobs
132

Products & Portfolio (29)

21 discontinued products not shown

ACETAMINOPHEN
acetaminophen
Peak
INTRAVENOUS · SOLUTION
12.1 Mechanism of Action The precise mechanism of the analgesic and antipyretic properties of acetaminophen is not established but is thought to primarily involve central actions. 12.2 Pharmacodynamics Acetaminophen has been shown to have analgesic and antipyretic activities in animal and human studies. Single doses of acetaminophen up to 3,000 mg and repeated doses of 1,000 mg every 6 hours for 48 hours have not been shown to cause a significant effect on platelet aggregation. Acetaminophen does not have any immediate or delayed effects on small-vessel hemostasis. Clinical studies of both healthy subjects and patients with hemophilia showed no significant changes in bleeding time after receiving multiple doses of oral acetaminophen. 12.3 Pharmacokinetics Distribution The pharmacokinetics of acetaminophen have been studied in patients and healthy subjects up to 60 years old. The pharmacokinetic profile of acetaminophen has been demonstrated to be dose proportional in adults following administration of single doses of 500, 650, and 1,000 mg. The maximum concentration (Cmax) occurs at the end of the 15-minute intravenous infusion of acetaminophen. Compared to the same dose of oral acetaminophen, the Cmax following administration of acetaminophen is up to 70% higher, while overall exposure (area under the concentration time curve [AUC]) is very similar. Pharmacokinetic parameters of acetaminophen (AUC, C max , terminal elimination half-life [T 1/2 ], systemic clearance [CL], and volume of distribution at steady state [Vss]) following administration of a single intravenous dose of 15 mg/kg in children and adolescents and 1,000 mg in adults are summarized in . Table 4. Acetaminophen Pharmacokinetic Parameters Subpopulations Mean (SD) AUC 0-6h (μg x h/mL) C max (μg/mL) T 1/2 (h) CL (L/h/kg) Vss (L/kg) Neonates 62 (11) 25 (4) 7 (2.7) 0.12 (0.04) 1.1 (0.2) Infants 57 (54) 29 (24) 4.2 (2.9) 0.29 (0.15) 1.1 (0.3) Children 38 (8) 29 (7) 3 (1.5) 0.34 (0.10) 1.2 (0.3) Adolescents 41 (7) 31 (9) 2.9 (0.7) 0.29 (0.08) 1.1 (0.3) Adults 43 (11) 28 (21) 2.4 (0.6) 0.27 (0.08) 0.8 (0.2) The pharmacokinetic exposure of acetaminophen observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from pharmacokinetic data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a pharmacokinetic exposure similar to that observed in children age 2 years and older. At therapeutic levels, binding of acetaminophen to plasma proteins is low (ranging from 10% to 25%). Acetaminophen appears to be widely distributed throughout most body tissues except fat. Metabolism and Excretion Acetaminophen is primarily metabolized in the liver by first-order kinetics and involves three principal separate pathways: Conjugation with glucuronide, conjugation with sulfate, and oxidation via the cytochrome P450 e
mild to moderate pain in adultolder () Management of moderate to severe pain with adjunctive opioid analgesics in adultolder () Reduction of fever in adult+1 more
2015
8
ACETYLCYSTEINE
acetylcysteine
Post-LOE
INTRAVENOUS · INJECTABLE
Reduction Activity
lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen 1
2012
30
ACYCLOVIR SODIUM
acyclovir
Post-LOE
SMINJECTION · INJECTABLE
CLINICAL PHARMACOLOGY: Pharmacokinetics The pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during Phase 1/2 studies after single doses ranging from 0.5 to 15 mg/kg and after multiple doses ranging from 2.5 to 15 mg/kg every 8 hours. Proportionality between dose and plasma levels is seen after single doses or at steady-state after multiple dosing. Average steady-state peak and trough concentrations from 1-hour infusions administered every 8 hours are given in . Table 1: Acyclovir Peak and Trough Concentrations at Steady-State Dosage Regimen Cmax Ctrough 5 mg/kg q 8 h (n=8) 9.8 mcg/mL range: 5.5 to 13.8 0.7 mcg/mL range: 0.2 to 1 10 mg/kg q 8 h (n=7) 22.9 mcg/mL range: 14.1 to 44.1 1.9 mcg/mL range: 0.5 to 2.9 Concentrations achieved in the cerebrospinal fluid are approximately 50% of plasma values. Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated. Renal excretion of unchanged drug is the major route of acyclovir elimination accounting for 62% to 91% of the dose. The only major urinary metabolite detected is 9-carboxymethoxymethylguanine accounting for up to 14.1% of the dose in patients with normal renal function. The half-life and total body clearance of acyclovir are dependent on renal function as shown in . Table 2: Acyclovir Half-life and Total Body Clearance Creatinine Clearance (mL/min/1.73 m) Total Body Clearance Half-Life (hr) (mL/min/1.73 m) (mL/min/kg) >80 2.5 327 5.1 50 to 80 3 248 3.9 15 to 50 3.5 190 3.4 0 (Anuric) 19.5 29 0.5
initialrecurrent mucosalcutaneous herpes simplex (HSV-1+6 more
1998
30
ACYCLOVIR SODIUM
acyclovir
Post-LOE
SMINJECTION · INJECTABLE
CLINICAL PHARMACOLOGY: Pharmacokinetics The pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during Phase 1/2 studies after single doses ranging from 0.5 to 15 mg/kg and after multiple doses ranging from 2.5 to 15 mg/kg every 8 hours. Proportionality between dose and plasma levels is seen after single doses or at steady-state after multiple dosing. Average steady-state peak and trough concentrations from 1-hour infusions administered every 8 hours are given in . Table 1: Acyclovir Peak and Trough Concentrations at Steady-State Dosage Regimen Cmax Ctrough 5 mg/kg q 8 h (n=8) 9.8 mcg/mL range: 5.5 to 13.8 0.7 mcg/mL range: 0.2 to 1 10 mg/kg q 8 h (n=7) 22.9 mcg/mL range: 14.1 to 44.1 1.9 mcg/mL range: 0.5 to 2.9 Concentrations achieved in the cerebrospinal fluid are approximately 50% of plasma values. Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated. Renal excretion of unchanged drug is the major route of acyclovir elimination accounting for 62% to 91% of the dose. The only major urinary metabolite detected is 9-carboxymethoxymethylguanine accounting for up to 14.1% of the dose in patients with normal renal function. The half-life and total body clearance of acyclovir are dependent on renal function as shown in . Table 2: Acyclovir Half-life and Total Body Clearance Creatinine Clearance (mL/min/1.73 m) Total Body Clearance Half-Life (hr) (mL/min/1.73 m) (mL/min/kg) >80 50 to 80 15 to 50 0 (Anuric) 2.5 3 3.5 19.5 327 248 190 29 5.1 3.9 3.4 0.5
initialrecurrent mucosalcutaneous herpes simplex (HSV-1+6 more
2024
30
ADENOSINE
adenosine
Post-LOE
INTRAVENOUS · SOLUTION
Adenosine Receptor Agonists
2017
30
ADENOSINE
adenosine
Post-LOE
INJECTION · INJECTABLE
Adenosine Receptor Agonists
atrial fibrillation
2018
30
ADENOSINE
adenosine
Post-LOE
INJECTION · INJECTABLE
Adenosine Receptor Agonists
atrial fibrillation
2005
30
AMIKACIN SULFATE
amikacin sulfate
Post-LOE
INJECTION · INJECTABLE
Mechanism of Action Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria.
the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteriaincluding Pseudomonas speciesEscherichia coli+7 more
2015
30
AMIODARONE HYDROCHLORIDE
amiodarone hydrochloride
Post-LOE
INJECTION · INJECTABLE
drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with prolonged administration, is to lengthen the cardiac action potential, a class III effect. The negative chronotropic effect of amiodarone in nodal tissues is similar to the effect of class IV drugs. In addition to blocking sodium channels, amiodarone blocks myocardial potassium channels, which contributes to slowing of conduction and prolongation of refractoriness. The antisympathetic action and the block of calcium and potassium channels are responsible for the negative dromotropic effects on the sinus node and for the slowing of conduction and prolongation of refractoriness in the atrioventricular (AV) node. Its vasodilatory action can decrease cardiac workload and consequently myocardial oxygen consumption. Intravenous amiodarone administration prolongs intranodal conduction (Atrial-His, AH) and refractoriness of the atrioventricular node (ERP AVN), but has little or no effect on sinus cycle length (SCL), refractoriness of the right atrium and right ventricle (ERP RA and ERP RV), repolarization (QTc), intraventricular conduction (QRS), and infra-nodal conduction (His-ventricular, HV). A comparison of the electrophysiologic effects of intravenous amiodarone and oral amiodarone is shown in the table below. Table 6: EFFECTS OF INTRAVENOUS AND ORAL AMIODARONE ON ELECTROPHYSIOLOGIC PARAMETERS ↔ No change Formulation SCL QRS QTc AH HV ERP ERP ERP RA RV AVN Intravenous ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↑ Oral ↑ ↔ ↑ ↑ ↔ ↑ ↑ ↑ At higher doses (>10 mg/kg) of intravenous amiodarone, prolongation of the ERP RV and modest prolongation of the QRS have been seen. These differences between oral and IV administration suggest that the initial acute effects of intravenous amiodarone may be predominately focused on the AV node, causing an intranodal conduction delay and increased nodal refractoriness due to slow channel blockade (class IV activity) and noncompetitive adrenergic antagonism (class II activity).
2002
30
ARSENIC TRIOXIDE
arsenic trioxide
Post-LOE
INJECTION · INJECTABLE
understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha.
2018
30
ASCORBIC ACID
ascorbic acid
Post-LOE
INTRAVENOUS · SOLUTION
(a disorder caused by severe deficiency in vitamin C) is unknown; however, administration of ascorbic acid in patients with scurvy is thought to restore the body pool of ascorbic acid.
vitamin C deficiencysymptoms of scurvy
2025
30
ATROPINE SULFATE
atropine sulfate
Peak
INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL · SOLUTION
muscarine-like actions of acetylcholine and other choline esters. Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters.
2018
30
View all 29 products

Pipeline & Clinical Trials

Supplemental Parenteral Nutrition
Parenteral Nutrition
N/A
Clinical Trials (1)
NCT06510348Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNtesTinal Dysfunction
N/A
Non-milked derived protein source formula diet
Acute Renal Failure
N/A
Clinical Trials (1)
NCT03715868Pre-operative Short-term Administration of a Formula Diet Containing a Non-milk-derived Protein Source for Prevention of Acute Kidney Injury After Cardiac Surgery
N/A
Screening Day Latin America
Nutritional Status
N/A
Clinical Trials (1)
NCT02583880Screening Day Latin America
N/A
oral nutritional supplement, food for special medical purposes
Cachexia
N/A
Clinical Trials (1)
NCT00851448Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients
N/A
High caloric, high protein ONS
Malnutrition
N/A
Clinical Trials (1)
NCT02938234Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Free Intake
N/A
N/A
Clinical Trials (1)
NCT00133978Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients
N/A
nutritional support program
Pancreatic Cancer
N/A
Clinical Trials (1)
NCT02626195Preoperative Nutritional Support in Malnutritional Cancer Patients
N/A
ketoanalogues of essential amino acids
Stage 4 Chronic Kidney Disease
N/A
Clinical Trials (1)
NCT03818568Supplemented Low Protein Diet and Progression of CKD
N/A
N/A
Clinical Trials (1)
NCT00662376Study on Safety, Tolerance and Metabolic Effects of a Nutritional Supplement, Given as a Drink Before Gallbladder Surgery
N/A
N/A
Clinical Trials (1)
NCT00503334Preoperative Oral Nutritional Supplement (preOP Booster) in Visceral Surgery
N/A
The German Patient Blood Management Network
Clinical Safety of a PBM Program
N/A
Clinical Trials (1)
NCT02147795The German Patient Blood Management Network
N/A
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on th
Crohn Disease
N/A
Clinical Trials (1)
NCT05051943A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
N/A
sucrosomial iron
Iron-deficiency
N/A
Clinical Trials (1)
NCT04250298Sucrosom5al Iron Supplementation in Blood Donors
N/A
Randomised 20g Protein Supplement
Healthy Male Volunteers Over 65
N/A
Clinical Trials (1)
NCT07038655Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique
N/A
Low protein diet with Fresubin® renal
Chronic Kidney Disease
N/A
Clinical Trials (1)
NCT05330663Low Protein Renal Formula as Meal Replacement in Predialysis CKD Patients
N/A
High caloric, high protein ONS
Malnutrition
N/A
Clinical Trials (1)
NCT02938247Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake
N/A
low protein diet + ketosteril
Acute Kidney Injury
N/A
Clinical Trials (1)
NCT02831062Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease
N/A
Renalive® LP, flavour Vanilla
CKD
N/A
Clinical Trials (1)
NCT06892249Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Outpatients in Taiwan
N/A
Three-Chamber Bags Retrospective Study in Spain
Parenteral Nutrition
N/A
Clinical Trials (1)
NCT03284398Three-Chamber Bags Retrospective Study in Spain
N/A
Total Parenteral Nutrition with Glutamine
Moderate to Severe Trauma, as Defined by an
N/A
Clinical Trials (1)
NCT01250080Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.
N/A
Chronic Kidney Disease Observational Database - Taiwan
Chronic Kidney Insufficiency
N/A
Clinical Trials (1)
NCT03619564Chronic Kidney Disease Observational Database - Taiwan
N/A
ProvideXtra DRINK
Enteral Nutrition
N/A
Clinical Trials (1)
NCT00600678Gastric Emptying Study After Administration of a High Caloric Sip Feed
N/A
Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critica
Critical Illness
N/A
Clinical Trials (1)
NCT04143503Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients
N/A
N/A
Clinical Trials (1)
NCT04240600Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay
N/A
International Nutrition Audit in FORegut TuMors
Head and Neck Cancer
N/A
Clinical Trials (1)
NCT02829489International Nutrition Audit in FORegut TuMors
N/A
Lactulose crystals 10 g
Blood Glucose
N/A
Clinical Trials (1)
NCT02968498Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers
N/A
Rational Fluid Therapy in Germany
Patients in ICU
N/A
Clinical Trials (1)
NCT01122277Rational Fluid Therapy in Germany
N/A
Nutrition Emulsion
Gastrointestinal Cancer
N/A
Clinical Trials (1)
NCT05606848To Test the Food for Special Medical Purpose in Perioperative Patients With Gastrointestinal Cancer
N/A
Effects of Shoulder Edema on Intubated Tube in Patients Undergoing Shoulder Arthroscopy
Arthroscopy
N/A
Clinical Trials (1)
NCT02184702Effects of Shoulder Edema on Intubated Tube in Patients Undergoing Shoulder Arthroscopy
N/A
bIosimilar of aDalimumab, an European evAluation
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT05190484bIosimilar of aDalimumab, an European evAluation
N/A
Real World Use of Tocilizumab Biosimilar studY
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT06247722Real World Use of Tocilizumab Biosimilar studY
N/A
Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients
Surgery
N/A
Clinical Trials (1)
NCT01820949Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients
N/A
Combined cycle ergometry and bolus amino acid supplementation
Critical Illness
N/A
Clinical Trials (1)
NCT04099108Effect of Combined IV Bolus Amino Acid Supplementation and Mobilisation on Skeletal Muscle During the First 10 Days in the ICU: A RCT
N/A
Observational study: Supplemented protein-restricted diet
Chronic Kidney Disease
N/A
Clinical Trials (1)
NCT02649205Observational Study on Chronic Kidney Disease Treatment With a Ketosteril Supplemented Protein-restricted Diet
N/A
α-Keto Acid with restricted protein diet
Renal Function Disorder
N/A
Clinical Trials (1)
NCT01255020Renal Protective Effects of Restricted Protein Dietary With α-keto Acid in CAPD Patients
N/A
oral nutrition supplement, food for special medical purposes
Cachexia
N/A
Clinical Trials (1)
NCT00852020Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients
N/A
calorie restriction
Acute Renal Failure
N/A
Clinical Trials (1)
NCT01534364Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery
N/A
Fresubin® powder fibre
Malnutrition
N/A
Clinical Trials (1)
NCT04474886Oral Nutritional Supplement for the Patient With or at Risk of Malnutrition
N/A
QoL and developed questionnaires for healthcare research
Tumors and Home Parenteral Nutrition
N/A
Clinical Trials (1)
NCT03425435Quality of Care of Oncological Patients With HPN
N/A
Lignocaine, Dexmedetomidine, Sevoflurane, Paracetamol, Parecoxib
Opioid-Free Anaesthesia
N/A
Clinical Trials (1)
NCT05681429Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy
N/A
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimuma
Crohn Disease
N/A
Clinical Trials (1)
NCT05598684SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
N/A
Nutrition Insights Day Asia
Nutritional Status
N/A
Clinical Trials (1)
NCT03606603Nutrition Insights Day Asia
N/A
N/A
Clinical Trials (1)
NCT01025167The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients
N/A
N/A
Clinical Trials (1)
NCT02503527Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy
N/A
Oral nutritional supplement, food for special medical purposes
Diabetes
N/A
Clinical Trials (1)
NCT01241695Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients
N/A
Observational study: Supplemented protein-restricted diet
Chronic Kidney Disease
N/A
Clinical Trials (1)
NCT02756520Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
N/A
Observational study: Supplemented protein-restricted diet
Chronic Kidney Disease
N/A
Clinical Trials (1)
NCT02746133Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-027-CNI)
N/A
Fresubin Plant-based drink vanilla©
Risk of Malnutrition
N/A
Clinical Trials (1)
NCT07399886Plant-based Versus Animal-based Oral Nutritional Supplements
N/A
Fresubin® Protein Energy DRINK
Hemodialysis Complication
N/A
Clinical Trials (1)
NCT05333692Oral Nutritional Supplementation of Hemodialysis Patients
N/A
Swallow therapy in combination with individual dietary counselling
Neoplasms, Head and Neck
N/A
Clinical Trials (1)
NCT01110980Normalcy of Food Intake in Head and Neck Cancer Patients
N/A

Open Jobs (132)

PACKER/INSPECTOR - 3rd Shift

Grand Island, NY
Yesterday
$18 - $20/hr

Manager Validation

Wilson, NC
Yesterday
$91K - $127K/yr

Human Resources Generalist

Wilson, NC
Yesterday
$61K - $86K/yr

Regulatory Specialist

Lake Zurich, IL
Yesterday
$101K - $110K/yr

Warehouse Associate I

Duncan, SC
Yesterday
$21/hr

Associate Scientist Microbiology (12-Hour Overnight Shift)

Melrose Park, IL
2d ago
$28/hr

Sr Engineer (Medical Device Reliability)

Warrendale, PA
2d ago
$85K - $95K/yr

Human Resources Generalist

Melrose Park, IL
2d ago

Electro Mechanical Assembler I (3rd Shift)

Warrendale, PA
2d ago
$18 - $19/hr

Project Manager (Technical)

Lake Zurich
5d ago
$95K - $110K/yr

Category Manager (Purchasing – R&D and Professional Services)

Lake Zurich, IL
5d ago
$125K - $147K/yr

Sr Analyst, Contract Marketing (Contract Compliance)

Lake Zurich, IL
6d ago
$80K - $95K/yr

Sr. Calibration Specialist

Wilson, NC
6d ago

Manager, CRM System Operations

Lake Zurich, IL
6d ago
$120K - $135K/yr

Sr Engineer (Mechanical)

Warrendale, PA
6d ago
$85K - $96K/yr

FILLING MACHINE OPERATOR (Bldg 4) - 2nd Shift

Grand Island, NY
6d ago
$22 - $23/hr

Intern - Sustaining Engineering (Electrical)

Warrendale, PA
6d ago
$22/hr

TERMINAL STERILIZATION OPERATOR - 3rd Shift

Grand Island, NY
6d ago

Manager, Maintenance & Engineering

Wilson, NC
6d ago
$91K - $127K/yr

FILLING MACHINE OPERATOR (Bldg 4) - 3rd Shift

Grand Island, NY
6d ago
$22 - $24/hr

Systems Administrator

Melrose Park, IL
1w ago
$70K - $85K/yr

Intern - Investor Relations

Lake Zurich, IL
1w ago
$20/hr

Associate Scientist-4th Shift (Weekends)

Grand Island, NY
1w ago
$23/hr

Production Technician I (12-Hour Overnight Shift)

Melrose Park, IL
1w ago
$24/hr

Principal Engineer (Product Sustaining)

Warrendale, PA
1w ago
$100K - $115K/yr
View all 132 open positions →
Interview Prep Quick Facts
Founded: 1999
Portfolio: 405 approved products, 114 clinical trials
Top TAs: Oncology, Nephrology, Infectious Diseases
H-1B (2023): 2 approvals
Publications: 25 in PubMed
Open Roles: 132 active jobs
Portfolio Health
Pre-Launch3 (1%)
Launch4 (1%)
Growth4 (1%)
Peak28 (7%)
LOE Approaching55 (14%)
Post-LOE311 (77%)
405 total products
Therapeutic Area Focus
Oncology
40 marketed16 pipeline
Nephrology
14 marketed16 pipeline
Infectious Diseases
21 marketed3 pipeline
Cardiovascular
19 marketed2 pipeline
Neurology
20 marketed
Immunology
12 marketed8 pipeline
Respiratory
13 marketed2 pipeline
Hematology
13 marketed
Marketed
Pipeline

Hiring Trend

Actively Hiring
132
Open Roles
+132
Added
-0
Filled/Removed

Based on last 2 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub